Evidence map›Paper›PMID 21802343›Full record

ReviewCytokine & growth factor reviews2011

CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.

Mingli Liu, Shanchun Guo, Jacqueline M Hibbert, Vidhan Jain, Neeru Singh, Nana O Wilson, Jonathan K Stiles

Abstract readReview
In one paragraph

Review in Cytokine & growth factor reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 485 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
485citing papers in PubMed, 6 pooled it
44.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

485 citing papers in PubMed, 6 syntheses or guidelines pooled it, 744 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Characterization of an isogenicInfection and immunity · 2026
    Article
  19. Article
  20. Article

425 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mingli LiuDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA. mliu@msm.edu
Shanchun Guo
Jacqueline M Hibbert
Vidhan Jain
Neeru Singh
Nana O Wilson
Jonathan K Stiles
Morehouse School of Medicine · USNational Institute of Malaria Research · IN

Funding

TISSUE CULTURE MODEL FOR RETINITIS PIGMENTOSA--A MOLECULAR APPROACHR25GM058268 · NIGMS · MOREHOUSE SCHOOL OF MEDICINE · PI HARRIS-HOOKER, SANDRA, STILES, JONATHAN K. · 1998 to 2023
$16.5M
Morehouse School of Medicine Training in Genomics and Hemoglobinopathies ProgramR90HG004151 · NHGRI · MOREHOUSE SCHOOL OF MEDICINE · PI STILES, JONATHAN K. · 2006 to 2010
$419k
Cerebral Malaria Neurological Disorders in IndiaR21TW006804 · FIC · MOREHOUSE SCHOOL OF MEDICINE · PI STILES, JONATHAN K. · 2003 to 2005
$355k
Morehouse School of Medicine Training in Genomics and Hemoglobinopathies ProgramT90HG004004 · NHGRI · MOREHOUSE SCHOOL OF MEDICINE · PI STILES, JONATHAN K. · 2006 to 2010
$308k
FIC NIH HHS R21 TW006804NCRR NIH HHS RR033062NHGRI NIH HHS 1T90-HG004151-01NHGRI NIH HHS R90 HG004151NHGRI NIH HHS T90 HG004004NIGMS NIH HHS R25 GM058268
6 · The paper itself

Abstract

C-X-C motif chemokine 10 (CXCL10) also known as interferon γ-induced protein 10 kDa (IP-10) or small-inducible cytokine B10 is a cytokine belonging to the CXC chemokine family. CXCL10 binds CXCR3 receptor to induce chemotaxis, apoptosis, cell growth and angiostasis. Alterations in CXCL10 expression levels have been associated with inflammatory diseases including infectious diseases, immune dysfunction and tumor development. CXCL10 is also recognized as a biomarker that predicts severity of various diseases. A review of the emerging role of CXCL10 in pathogenesis of infectious diseases revealed diverse roles of CXCL10 in disease initiation and progression. The potential utilization of CXCL10 as a therapeutic target for infectious diseases is discussed.

Indexed as

Angiogenesis InhibitorsAnimalsApoptosisBiomarkersChemokine CXCL10ChemotaxisGene Expression RegulationHumansInfectionsInflammationReceptors, CXCR3Severity of Illness IndexAngiogenesis InhibitorsBiomarkersChemokine CXCL10CXCL10 protein, humanCXCR3 protein, humanReceptors, CXCR3

Identifiers

PMID21802343
PMCPMC3203691
OpenAlexW2053384955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.